ASXL1 and myelodysplastic syndrome: According to the WHO 2016 diagnostic criteria, ASXL1‐mutated patients had a higher percentage of MDS with the excess blasts subtype (MDS‐EB‐1 and MDS‐EB‐2) compared to ASXL1 non‐mutated patients (p = 0.042) (Figure S2D).